Status:
UNKNOWN
RECO in the Endovascular Treatment of Acute Ischemic Stroke
Lead Sponsor:
Beijing Tiantan Hospital
Conditions:
Intracranial Artery Occlusion With Infarction (Disorder)
Eligibility:
All Genders
18+ years
Brief Summary
Investigate Reco ® ,the first clot retriever in china as the primary therapyand remedies in the real world.
Detailed Description
Endovascular thrombectomy (EVT) is effective and safe for acute ischemic stroke (AIS) caused by large vessel occlusion (LVO) in major clinical trials. Whether the benefit of EVT in randomized trials c...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old
- Diagnosis of acute ischemic stroke
- Imaging confirmed intracranial large artery occlusion (LVO): intracranial internal carotid artery (ICA T/L), middle cerebral artery (MCA M1/M2), anterior cerebral artery (ACA A1/A2), basilar artery (BA), vertebral artery (VA V4), and posterior cerebral artery (PCA P1);ASPECT or PC-ASPECT ≥ 6
- Initiation of any type of endovascular treatment (EVT), including intra-arterial thrombolysis, mechanical thrombectomy, angioplasty, and stenting
- The patient or the patient's legal representative is able and willing to sign the informed consent
Exclusion
- Isolated cervical ICA or VA occlusion;
- No evidence of LVO on DSA.
Key Trial Info
Start Date :
May 22 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 30 2022
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04840719
Start Date
May 22 2020
End Date
July 30 2022
Last Update
April 14 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Tiantan Hospital
Beijing, Beijing Municipality, China, 100010